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Objects: Isolated cleft palate (CPO) is the rarest form of oral clefting affecting 1-25 
per 10 000 newborns worldwide. There is increasing evidence for the different 
pathogenetic backgrounds of CPO and cleft lip with or without cleft palate. The role 
of environmental factors in the origin of non-syndromic and syndromic CPO is un-
clear in most patients. The aim of this study was to estimate possible maternal risk 
factors in the origin of CPO.
Setting and Sample Population: The Hungarian Case-Control Surveillance of 
Congenital Abnormalities contains data of 32 345 birth defect cases and 57 231 
control newborns. The study samples included 751 cases with isolated CPO, 1196 
matched controls and 57 231 population controls.
Material and Methods: Maternal diseases during pregnancy in cases and population 
controls were compared, and adjusted ORs with 95% CI were calculated in a multi-
variable unconditional logistic regression model.
Results: Beyond the well-known robust female excess (58.9%)—maternal smoking (OR 
with 95% CI: 2.34, 1.94-2.81) medically recorded maternal anaemia, threatened abor-
tion and excessive vomiting in pregnancy were associated with a higher risk for CPO 
in the offspring. An elevated risk was found in Graves’ disease (OR: 4.30, 1.74-10.62), 
epilepsy (OR: 4.64, 2.44-8.82), migraine (OR: 2.82, 1.18-6.76) and essential hyperten-
sion (OR: 2.33, 1.32-4.10). Among acute diseases common cold (OR: 4.94, 3.48-7.03), 
acute respiratory infections (OR: 4.20, 1.49-11.82), influenza (OR: 2.95, 1.75-4.95), 
pulpitis (OR: 7.85, 2.80-22.03), cholecystitis (OR: 3.15, 1.16-8.60), acute urinary tract 
infections (OR: 4.08, 2.22-7.49) and pelvic inflammatory diseases (OR: 3.93, 1.62-9.53) 
during pregnancy also were associated with an increased risk for developing CPO.
Conclusion: The findings of this study suggest that maternal diseases and lifestyle 
factors during the first trimester play a significant role in the development of isolated 
cleft palate.
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1  | INTRODUC TION
Orofacial clefts are common birth defects, with an estimated world-
wide incidence of around 1.7 per 1000 live born babies.1 Hungarian 
data showed a cleft prevalence of 2.02/1000.2 Babies born with 
these types of anomalies have feeding difficulties and are often 
developing conductive hearing loss, speech problems, dental anom-
alies and associated social and psychological issues.3 Patients suf-
fering from orofacial clefts may require multiple surgical, dental, 
orthodontic, speech, hearing and psychological treatments through-
out childhood and adolescence.
Isolated cleft palate (cleft palate only, CPO) is the rarest form of oral 
clefting affecting 1-25 per 10 000 newborns worldwide.4 There is in-
creasing evidence for the different pathogenetic backgrounds of CPO 
and cleft lip with or without cleft palate (CL ± CP). CPO is frequently a 
component congenital abnormality (CA) in chromosomal aberrations or 
gene mutations (WNT3, TGIF, ZIC2, PTCH1, GLI2 and CDON).
Several candidate genes have also been identified in the origin of 
non-syndromic and syndromic CPO.3,5
However, the role of environmental factors is unclear in the vast 
majority of patients with CPO, except for the deleterious effect of 
smoking during pregnancy. Active or passive maternal smoking in-
creases the risk of CPO with more than 25%.6,7
Thus, the aim of the present study was to estimate the role of 
maternal lifestyle factors (eg age, education and smoking) and acute 
or chronic maternal diseases during pregnancy in the origin of CPO, 
using the population-based Hungarian Case-Control Surveillance of 
Congenital Abnormalities (HCCSCA).
2  | MATERIAL S AND METHODS
2.1 | The Hungarian Congenital Abnormality 
Registry (HCAR)
The HCAR was established in 1962 as the first national-based reg-
istry of CAs in the world.8 Reporting of patients as cases with CA to 
the HCAR is mandatory for physicians from birth until the end of the 
first post-natal year. Most cases are reported by obstetricians and 
paediatricians (in Hungary, practically all deliveries occur at inpatient 
obstetric departments). Since 1984, pre-natal diagnostic centres were 
also asked to report malformed foetuses diagnosed pre-natally with 
or without elective termination of pregnancy to the HCAR. Two spe-
cialized geneticists of the HCAR examined the affected children. The 
physical examination contributed to CA-diagnosis confirmation and 
helped to differentiate the subgroups of CAs.
2.2 | The Hungarian Case-Control Surveillance of 
Congenital Abnormalities (HCCSCA)
Cases with CAs including CPO in the HCAR were enrolled to the 
HCCSCA if they met all the following selection criteria:
1. Reported to the HCAR within 3 months after birth or elective 
termination of pregnancy.
2. Did not have any of three mild CAs (dislocation of the hip, con-
genital inguinal hernia and large hemangioma).
3. Did not have CA-syndromes caused by gene mutations or chro-
mosomal aberrations with pre-conceptional origin.
Controls were defined as newborn infants without CAs, and they 
were matched to cases according to sex, birth week and district of 
parents’ residence. These controls were selected from the National 
Birth Registry of the Central Statistical Office based on case lists for 
each quarter of the years from the HCCSCA. In general, 2 controls 
were selected for each malformed newborn. If controls were twins, 
only one of them was randomly selected for the HCCSCA. In addi-
tion, if selected controls had any CA, these infants were excluded 
from the group of controls.
The HCCSCA was established in 1980. The collection of data 
was changed in 1997, slightly modifying the structure of the 
HCCSCA also. All data collected in the HCCSCA between 1980 
and 2009 were unified into a validated single database that is now 
open for examination. This dataset of the HCCSCA is evaluated in 
this paper.
2.3 | Data collection
Data about maternal lifestyle factors, maternal diseases dur-
ing pregnancy and occurrence of CPO were obtained via three 
sources:
1. Prospective, medically recorded data. Mothers were requested to 
send the pre-natal maternity logbook and every medical record 
concerning their diseases during the study pregnancy and their 
child's CA. Pre-natal care was mandatory for pregnant women; 
thus, nearly 100% of them attended pre-natal care, on average 
7 times between the 6th gestational week and delivery. The 
task of obstetricians in pre-natal care was to record all maternal 
diseases and medicinal products used by women during the 
study pregnancy in the logbook.
2. Retrospective, maternal self-reported information. A structured 
questionnaire and a printed informed consent were also mailed to 
the mothers of cases and controls. It comprised questions regard-
ing maternal diseases and related drug treatments, pregnancy 
supplements. Mothers were asked to read the enclosed list as a 
memory aid before they filled in the questionnaire and signed the 
informed consent.
3. Supplementary data collection. After 1996, regional nurses made 
home visits to all cases and controls. They helped mothers collect 
their medical records and fill in the questionnaire. The collection 
procedure was impugned by one mother in 2002 alluding to con-
cerns of data privacy. The activity of the HCCSCA was stopped 
when the legal procedure started in 2003 and the HCCSCA could 
continue its work again only in 2005.
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The following data are available for each case and control preg-
nancy: CA(s), gender, maternal age, paternal age, birth year/month/
date, birthweight, gestational age, area of mother's living, birth order, 
mother's and father's qualification, employment status and type of em-
ployment, mother's marital status, outcome of previous pregnancies, 
maternal diseases during pregnancy (according to pregnancy months), 
drug intake during pregnancy (according to pregnancy months), moth-
er's smoking habits and alcohol consumption patterns.
2.4 | Evaluation of cases with CPO
Cases with multiple/syndromic birth defects were excluded from 
the study.
Since the critical period of CPO is estimated to be between the 
70th and the 99th post-conceptional days, that is 84th and 113rd 
gestational days calculated from the first day of the last menstrual 
period,9 exposures were evaluated during the 3rd and 4th gesta-
tional months.10 The effects of maternal illnesses were analysed if at 
least 0.5% of mothers were affected.
Controls were differentiated into two groups: matched controls 
(two controls were matched to the cases with CPO) and the so-called 
population controls including all controls in the HCCSCA.
2.5 | Statistical analysis
Quantitative variables such as mean maternal age and birth order were 
evaluated by Student's t test. Chi-squared test was used for the evalu-
ation of maternal age distribution, birth order and employment status. 
For categorical variables, pregnancy complications, maternal diseases, 
drugs and pregnancy supplements adjusted odds ratios (OR) with 95% 
confidence intervals (CI) were estimated. A multivariable conditional lo-
gistic regression model was used to compare maternal risk factors of 
cases with matched controls. Maternal illnesses of cases and population 
controls were also compared and adjusted ORs with 95% CI were calcu-
lated in a multivariable unconditional logistic regression model. Among 
confounding factors maternal age (continuous variable), birth order (par-
ity) (2 vs. 1, 3+ vs. 1) and employment status (skilled/semiskilled worker 
vs. professional/managerial, unskilled worker/other vs. professional/
managerial) as an indicator of socioeconomic status were considered.11
3  | RESULTS
3.1 | General characteristics of the participants
In total, 2503 cases with orofacial clefts were identified in the 
HCCSCA between 1980 and 2009, among them 797 (31.8%) pre-
senting with CPO at birth. Of these newborns, 46 cases (5.8%) 
with cleft palate diagnosed as part of multiple CA-syndromes were 
excluded from the analysis. Thus, 751 isolated CPO cases were 
evaluated. The number of matched controls was 1196. Live births 
in Hungary between 1980 and 2009 were 3 009 303; thus, 57 231 
population controls represented 1.9% of all Hungarian births.
3.2 | Maternal lifestyle factors and CPO risk
Socio-demographic data of cases and controls are presented in 
Table 1. No significant differences between the case and control 
groups have been found in mean maternal or paternal ages, although 
the proportion of both younger and older mothers was lower in the 
CPO group as compared to matched controls.
The distribution of maternal employment status indicated a higher 
socioeconomic status of case mothers; however, these differences 
were also not significant. The proportion of managerial mothers was 
19.9% (N = 149) in the group of cases and 14.5% (N = 173) in the 
group of matched controls, while that of unskilled mothers were 1.3% 
(N = 10) in the CPO group, 4.1% (N = 49) among matched controls 
and 3.5% (N = 2.022) in population controls. No significant differences 
were found in birth order (primiparous women: 371 [51.5%] vs. 595 
[54.2%] and 28 301 (54.9%) in the control groups). The well-known 
gender differences among CPO cases were also verified in this data-
base. Namely, CPO was significantly more common in females then 
males (442 [58.9%] females, 307 [40.9%] males, in 2 cases we found 
no data on gender). The birthweight of newborns affected by CPO 
was significantly lower than in the control groups (3076 vs. 3315 and 
3295 g in matched and population controls, respectively).
A highly significant association has been found between mater-
nal smoking and the development of CPO. The proportion of smoker 
mothers was 18.64% in the CPO group while 8.44% and 8.94% in the 
matched (OR: 2.5 [95% CI: 1.9-3.3]) and population (OR: 2.3 [95% CI: 
1.9-2.8]) control groups, respectively.
3.3 | Maternal diseases during pregnancy and 
CPO risk
Among medically recorded pregnancy complications the incidences 
of anaemia (OR: 1.8 [95% CI: 1.3-2.7]), threatened abortion (OR: 
4.9 [95% CI: 3.1-7.9]) and severe nausea-vomiting (OR: 3.2 [95% CI: 
2.6-4.0]) were higher in the mothers of cases than in the mothers of 
matched controls. Detailed data are shown in Table 2.
The incidences of acute and chronic maternal disease groups 
with significantly altered odds ratios for CPO are presented in 
Table 3 and Table 4. Among acute illnesses various infectious, 
inflammatory diseases showed a higher incidence in the mothers 
of cases than in the mothers of matched and population controls 
(influenza (OR:1.8, 95% CI:1.3-2.5), acute upper respiratory in-
fections (OR:2.5, 95% CI:1.9-3.1), acute lower respiratory infec-
tions (OR:2.4, 95% CI:1.4-4.2), urogenital infections (OR:2.0, 95% 
CI:1.4-2.8), etc, and unspecified high temperature (OR:8.1, 95% 
CI:2.9-22.6)). Besides this group, herpes simplex infection in the 
mothers also increased the risk of CPO significantly (OR:14.8, 
vCI:5.7-38.5).
     |  177ÁCS et al.
The evaluation of chronic maternal diseases was based on medi-
cal records in the pre-natal maternity logbook again including at least 
4 mothers of cases (0.5%). Maternal Graves’ disease (OR:4.3, 95% 
CI:1.7-10.6), epilepsy (OR:4.6, 95% CI:2.4-8.8), migraine (OR:2.8, 
95% CI:1.2-6.8), essential hypertension (OR:1.7, 95% CI:1.2-2.4) and 
neuro-musculoskeletal pain syndromes (OR:6.7, 95% CI:2.7-16.8) oc-
curred more frequently in the mothers of 751 cases than in the moth-
ers of matched or population controls. Similarly, elevated odds ratios 
for CPO have been found among mothers suffering from cholelithiasis 
(OR:5.6, 95% CI:2.2-13.8) or urolithiasis (OR:4.2, 95% CI:1.7-10.2).
TA B L E  2   Number of pregnancy complications during the study pregnancy and the critical period of CPO in case mothers, matched and 







(N = 1196) Comparison
Population 
controls 
(N = 57 231) Comparison
No. % No. % OR 95% CI* P values No. % OR 95% CI* P values
Anaemia complicating 
pregnancy
58 7.7 52 4.3 1.84 1.25-2.71 <.01 3942 6.9 1.13 0.86-1.48 .37
Threatened abortion 69 9.2 24 2.0 4.94 3.08-7.94 <.01 3331 5.8 1.64 1.27-2.10 <.01
Excessive vomiting in 
pregnancy
262 34.9 172 14.4 3.19 2.56-3.98 <.01 19 169 33.5 1.06 0.91-1.24 .42
Note: Significant differences in bold (P < .05).
TA B L E  1   General characteristics of the cases, matched controls and population controls
 
CPO (No: 751)
Matched controls (No: 
1196)
P values
Population controls (No: 
57 231)
P valuesMean SD Mean SD Mean SD
Paternal age 29.35 6.33 29.49 6.29 .65 31.14 6.88* <.01
Maternal age 26.62 4.46 26.34 5.83 .26 27.76 6.38* <.01
 No. % No. %  No. %  
<23 184 24.53 375 31.35* <.01 14 710 25.70 .06
23-33 482 64.27 611 51.09* <.01 37 496 65.52 .06
>33 84 11.20 210 17.56* <.01 5024 8.78 .06
Maternal education No. % No. %  No. %  
Managerial 149 19.87 173 14.49 .32 11 057 19.32 .64
Professional 214 28.48 378 31.59 .32 17 166 29.99 .64
Skilled worker 209 27.81 322 26.96 .32 14 898 26.03 .64
Semiskilled 169 22.52 274 22.90 .32 12 088 21.12 .64
Unskilled 10 1.32 49 4.06 .32 2022 3.53 .64
Birth order No. % No. %  No. %  
Primiparous 371 51.46 595 54.19 .25 28 301 54.90 .06
Multiparous 350 48.54 503 45.81 .25 23 249 45.10 .06
Gender No. % No. %  No. %  
Male 307 40.93 492 41.13 <.01 37 006 64.66* <.01
Female 442 58.93 704 58.86 <.01 20 179 35.26* <.01
n.a. 2 0.27 1 0.08  46 0.08  
 Mean SD Mean SD  Mean SD  
Birthweight (g) 3076 451.65 3315* 387.00 <.01 3295* 398.34 <.01
Birth week 39.03 1.71 39.41* 1.35 <.01 39.7* 1.85 <.01
 No. % No. %  No. %  
Maternal smoking 140 18.64 101 8.44* <.01 5114 8.94* <.01
*P < .05. 
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4  | DISCUSSION
The aim of the present study was to investigate the association of ma-
ternal diseases and lifestyle factors with the risk of CPO based on the 
comparison of mothers of cases and matched and population controls.
Analysing the socio-demographic data a role of higher paternal 
age in the development of CPO could not be identified, although a 
causative role had previously been described.12,13 Active or passive 
maternal smoking is a well-known risk factor in CPO occurrence6,7 
Our results are in accordance with the previous findings; however, in 
this study, odds ratios of maternal smoking were 2.5 and 2.3 as com-
pared to the matched and population control groups, respectively. 
On the other hand, Lorente et al could not show the elevated risk of 
CPO among tobacco using mothers.14
The possible correlation between cleft palate and lower birth-
weight needs to be clarified in further studies; however, the 
TA B L E  3   Number of acute maternal diseases during the study pregnancy and the critical period of CPO in case mothers, matched and 






(N = 1196) Comparison
Population 
controls 
(N = 57 231) Comparison
No. % No. % OR 95% CI* P values No. % OR 95% CI* P values
Herpes simplex 
infection
5 0.7 0 0.0 n.a.  26 0.0 14.75 5.65-38.51 <.01
Common cold 124 16.5 46 3.8 4.94 3.48-7.03 <.01 4079 7.1 2.58 2.12-3.13 <.01
Acute upper 
respiratory infections
72 9.6 22 1.8 5.66 3.48-9.21 <.01 2372 4.1 2.45 1.92-3.14 <.01
Acute lower respiratory 
infections
13 1.7 5 0.4 4.20 1.49-11.82 <.01 414 0.7 2.42 1.39-4.22 <.01
Influenza 41 5.5 23 1.9 2.95 1.75-4.95 <.01 1762 3.1 1.82 1.32-2.50 <.01
Pulpitis 4 0.5 0 0.0 n.a.  39 0.1 7.85 2.80-22.03 <.01
Cholecystitis 4 0.5 0 0.0 n.a.  97 0.2 3.15 1.16-8.60 <.01
Acute urinary tract 
infections
37 4.9 15 1.3 4.08 2.22-7.49 <.01 1458 2.5 1.98 1.42-2.77 <.01
Pelvic inflammatory 
diseases
17 2.3 7 0.6 3.93 1.62-9.53 <.01 1051 1.8 1.24 0.76-2.01 .39
High temperature 
(unspecified)
4 0.5 1 0.1 6.40 0.71-57.36 .06 38 0.1 8.06 2.87-22.64 <.01
Note: Significant differences in bold (P < .05).
TA B L E  4   Number of chronic maternal diseases during the study pregnancy and the critical period of CPO in case mothers, matched and 







(N = 1196) Comparison
Population 
controls 
(N = 57 231) Comparison
No. % No. % OR 95% CI* P values No. % OR 95% CI* P values
Thyrotoxicosis 
(Graves’ disease)
5 0.7 0 0.0 n.a.  89 0.2 4.30 1.74-10.62 <.01
Epilepsy 10 1.3 0 0.0 n.a.  166 0.3 4.64 2.44-8.82 <.01
Migraine 14 1.9 8 0.7 2.82 1.18-6.76 <.01 694 1.2 1.55 0.91-2.64 .10
Essential (primary) 
hypertension
30 4.0 21 1.8 2.33 1.32-4.10 <.01 1375 2.4 1.69 1.17-2.44 <.01
Constipation 11 1.5 3 0.3 5.91 1.64-21.26 <.01 571 1.0 1.48 0.81-2.69 .20




5 0.7 0 0.0 n.a.  54 57 6.72 2.69-16.82 <.01
Urolithiasis 5 0.7 2 0.2 4.00 0.77-20.68 .07 92 0.2 4.16 1.69-10.27 <.01
Note: Significant differences in bold (P < .05).
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significantly higher rate of maternal smoking among CPO mothers 
may play a role in growth restriction. The present findings revealed 
a significantly lower birthweight of infants with CPO as compared to 
the control groups. The same trend has been described in popula-
tions in Iran,15 Taiwan16 and Uganda.17
In the present study, a significant difference was shown in the 
development of CPO between anaemic and non-anaemic mothers. 
Literature data on this correlation are scarce. Similarly, but non-con-
clusive findings were published in India and in Japan.18,19 The delete-
rious effect of anaemia may be a consequence of embryonic hypoxia 
during the first trimester, since it has been described that hypoxia may 
result in insufficient growth of the facial processes in the developing 
embryo.20 The possible role of threatened abortion in the develop-
ment of cleft palate was already described more than 40 years ago21 
but since then similar findings have not been presented. In the study, 
dataset threatened abortion significantly increased the risk of devel-
oping CPO as compared either to matched or population controls. 
The theoretical pathomechanical background may be insufficient lev-
els of progesterone or human chorionic gonadotrophin (hCG).
An interesting elevation in the risk of CPO among mothers suf-
fering from excessive vomiting in the first 4 months of pregnancy 
was observed. The risk was significantly higher in cases than 
matched controls. However, this difference did not occur by com-
paring the case group to population controls. Excessive vomiting 
was accepted during the analysis if hyperemesis was recorded by 
the obstetrician in the pregnancy logbook. Hyperemesis in preg-
nancy is generally believed to exert a protective effect against 
miscarriages, preterm birth.22 Nausea and vomiting during preg-
nancy were also supposed to play a protective role against the 
development of some birth defects, for example cleft lip.23 The 
most widely accepted hypothesis explains the beneficial effects of 
nausea and vomiting by a larger placenta and a higher blood level 
of human chorionic gonadotropin and estrogens in hyperemetic 
pregnant women. This hormonal milieu may have a protective 
effect against some CAs. On the other hand, in accordance with 
our results, an association between severe nausea and vomiting 
in early pregnancy and the risk of neural tube defects have been 
described in Northern China.24
Acute maternal diseases that caused an elevated risk for CPO show 
a typical pattern, namely all of them are infectious diseases of various 
organs. The common causative pathway may be the presence of hy-
perthermia since high fever-related maternal diseases are supposed to 
result in an increased prevalence of birth defects.25 However, the pos-
sible role of inflammatory cytokines must also be taken into consider-
ation (eg pulpitis is generally not associated with high temperature, but 
it also caused an elevated risk for CPO). The role of influenza during 
pregnancy in the development of CPO should be emphasized, since 
this infection may be effectively prevented by vaccination.
Among chronic maternal diseases present during the first 
14 weeks of pregnancy, a higher risk of CPO was found among 
mothers suffering from hyperthyroidism as compared to population 
controls. We are not aware of similar observations in the literature, 
although the importance of better reporting congenital anomalies 
in children of mothers with Graves' disease has already been em-
phasized.26 In women with epilepsy, it is known that the risk of birth 
defects in general and orofacial clefts in their offspring is signifi-
cantly elevated. Present results are in accordance with the literature 
data.27,28 It is important to note that the possible teratogenic effect 
of antiepileptic drugs in these cases must also be taken into consid-
eration.29,30 An elevated risk of CPO in mothers with migraine was 
also presented. Some earlier studies could not identify any delete-
rious effect of maternal migraine on the development of birth de-
fects,31 but the analysis of the first part of the HCCSCA has already 
shown this increased risk.32 In the case of maternal migraine, it is not 
clear whether the elevated risk of cleft formation is a consequence 
of the illness itself or of the drugs used to alleviate its symptoms.33 
Our present findings showed an increased risk of CPO among moth-
ers suffering from cholelithiasis, urolithiasis or neuro-musculoskel-
etal pain syndromes as well. There are no available literature data 
reassuring this finding; thus, it may be supposed that this effect is 
caused by the use of pain killers or spasmolytic drugs.
The strengths of our study are connected with the large popu-
lation-based dataset of the HCCSCA in an ethnically homogeneous 
Hungarian (Caucasian) population. The CPO diagnosis has high ac-
curacy (or reliability) since cases were reported by medical doctors 
in the HCAR and the diagnosis was accepted in all cases within the 
dataset of the HCCSCA. This study included all acute and chronic 
maternal diseases and these exposure data were based on multiple 
sources including pre-natal maternity logbooks, which provided pro-
spective medically recorded data. The exposure time and potential 
confounders were known.
However, there are also some limitations of our study. Maternal 
diseases, lifestyle factors and pregnancy supplementations were 
based partly on retrospective maternal information burdened by 
recall bias.34 However, we accepted these associations only if they 
were confirmed by prospective medically recorded data. Another 
weakness of our study is that only cases born between 1980 and 
2009 were evaluated; thus, the results of recent medical progress 
could not be analysed in this field.
5  | CONCLUSIONS
Maternal smoking, anaemia, hyperemesis, acute inflammatory dis-
eases, influenza, Graves’ disease, epilepsy, migraine, essential hy-
pertension, neuro-musculoskeletal pain syndromes, cholelithiasis 
and urolithiasis occurred more frequently in the mothers of cases 
than in the mothers of matched or population controls. In conclu-
sion, the findings of this study suggest that maternal lifestyle factors 
and diseases during the first trimester play a significant role in the 
development of isolated cleft palate.
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